Thousand Oaks biotech Atara Biotherapeutics has squeezed out a narrow but meaningful opening with federal regulators after the U.S. Food and Drug Administration agreed to a limited path for resubmitting its cell therapy, tabelecleucel. The move sent the company's stock sharply higher on the day and gives partner Pierre Fabre a more defined, if tightly constrained, route to try again for U.S. clearance. The FDA guidance is procedural rather than an approval, and the companies still need to bolster the trial evidence to meet the agency's conditions.
FDA Signs Off On Single-Arm Strategy, With Strings Attached
In a Type A meeting, regulators told Atara and Pierre Fabre that a prospectively specified single-arm study paired with an appropriate historical control could be considered adequate to support a future marketing application, according to a company update on Business Wire. The agency's answer narrows the technical issue that derailed the file earlier but puts a spotlight on how the historical control and follow-up are defined. In practical terms, the resubmission will depend as much on methodological precision as on any new patient numbers.
Partner Plans More Patients, Longer Follow-Up
Reporting that reviewed the meeting, including coverage in OncLive, said Pierre Fabre, which holds the BLA for tab-cel, plans to submit an updated ALLELE dataset that adds patients and extends follow-up to strengthen both safety and efficacy measures. Those accounts note that regulators want the historical control prespecified and closely matched to the trial population before they will sign off on relying on single-arm data. Atara says it will keep supporting Pierre Fabre as the partner prepares the resubmission, with a further company update expected in the third quarter.
Market Pop And The Cash Runway
Investors did not wait around. Atara's shares nearly doubled on May 7 and closed that day around $9.93, a move that local business coverage flagged as a dramatic rebound. Trading volume spiked into the tens of millions of shares that session, according to market data. Atara's first-quarter filing and earnings release report $516,000 in revenue and a net loss of roughly $4.1 million, and the company says $4.8 million in after-quarter ATM proceeds plus cost cuts should extend its cash runway into mid-2027, according to its investor update from Atara Biotherapeutics.
Two CRLs Set The Stage
The new opening follows two earlier setbacks. Atara disclosed a January 2025 Complete Response Letter that cited manufacturing observations, then a second CRL in early January 2026 that concluded the single-arm ALLELE dataset was no longer adequate as filed. Both companies publicly criticized the 2026 decision and sought more engagement with the FDA at the time. That track record means regulators are likely to scrutinize how any added data directly tackles the agency's earlier concerns.
What Is At Stake For Patients
Tabelecleucel, marketed in Europe as Ebvallo, is intended for patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease, an ultra-rare, often rapidly progressive complication after organ or stem-cell transplant. The therapy is already authorized in Europe, and Pierre Fabre's program documents note that real-world and trial follow-up there will be folded into the resubmission package. If the resubmission meets the FDA's prespecified requirements, U.S. patients who currently lack approved options could gain access. If it falls short, the regulatory path stays murky.
Thousand Oaks Angle And What To Watch Next
The outcome underscores that Thousand Oaks remains plugged into high-stakes clinical programs with global partners, even as the sector whipsaws. Local reporting notes that Atara has sharply reduced its headcount in recent years and shifted substantial tab-cel responsibilities to Pierre Fabre as part of the commercialization and resubmission strategy. Next up: watch for the specifics of Pierre Fabre's resubmission filing, the third-quarter regulatory update Atara has forecast, and any new analyses showing exactly how the historical control will be specified and validated.
Sources: according to Business Wire, OncLive, Atara Biotherapeutics, and Los Angeles Business Journal.
